nach oben

Erschienen in:

01.10.2011

The Effect of Docosahexaenoic Acid on Visual Evoked Potentials in a Mouse Model of Parkinson’s Disease: The Role of Cyclooxygenase-2 and Nuclear Factor Kappa-B

verfasst von: Ozlem Ozsoy, Gamze Tanriover, Narin Derin, Nimet Uysal, Necdet Demir, Burcu Gemici, Ceren Kencebay, Piraye Yargicoglu, Aysel Agar, Mutay Aslan

Erschienen in: Neurotoxicity Research | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to investigate the effect of docosahexaenoic acid (DHA) on visual evoked potentials (VEPs) in a mice model of Parkinson’s disease (PD). Mice model was created by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and DHA was given by gavage. Cyclooxygenase-2 (COX-2), caspase-3 activities, nuclear factor kappa-B (NF-κB) and prostaglandin E2 (PGE2) levels were determined in substantia nigra (SN) and retina. Cyclooxygenase-2 intensities were also determined immunohistochemically. The tyrosine hydroxylase (TH) immunolabelling was significantly decreased in MPTP group compared to control. Docosahexaenoic acid decreased dopaminergic neuron death in MPTP + DHA group when compared to MPTP group. Mice treated with MPTP showed motor deficits as compared to control. Significant improvement was observed in MPTP + DHA group when compared to MPTP group. Treatment with MPTP significantly increased the activity of COX-2 and total COX in SN when compared to the control group. Docosahexaenoic acid caused a significant decrease in total COX and COX-2 activity in SN of mice given MPTP. Cyclooxygenase-2 showed strong immunostaining in MPTP group when compared to other groups in SN. Levels of PGE2 increased in MPTP group when compared to control in SN. Docosahexaenoic acid treatment in MPTP group reduced PGE2 in SN. Nuclear factor kappa-B levels were found to be decreased in SN of MPTP group. The mean latencies of P1, N1, P2, N2, P3, N3, P4, N4, and P5 VEP components were significantly prolonged in MPTP group when compared to control. In MPTP + DHA group, the mean latencies of all components except P5 returned to control values. Current data shows that DHA treatment improves prolonged VEPs latencies and locomotor activity.

Adams J (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28:613–619PubMedCrossRef

Araki T, Mizutani H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y (2001) Nitric oxide synthase inhibitors cause motor deficits in mice. Eur Neuropsychopharmacol 11:125–133PubMedCrossRef

Barbato L, Rinalduzzi S, Laurenti M, Ruggieri S, Accornero N (1994) Color VEPs in Parkinson’s disease. Electroencephalogr Clin Neurophysiol 92:169–172PubMedCrossRef

Barbeau A, Roy M, Bernier G, Campanella G, Paris S (1987) Ecogenetics of Parkinson’s disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci 14:36–41PubMed

Bazan NG (2009) Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids 81:205–211PubMedCrossRef

Beal MF (2001) Experimental models of Parkinson’s disease. Nat Rev Neurosci 2:325–334PubMedCrossRef

Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455PubMedCrossRef

Bodis-Wollner I (1997) Visual electrophysiology in Parkinson’s disease: PERG, VEP and visual P300. Clin Electroencephalogr 28:143–147PubMed

Bodis-Wollner I, Onofrj M (1982) System diseases and visual evoked potential diagnosis in neurology: changes due to synaptic malfunction. Ann N Y Acad Sci 388:327–348PubMedCrossRef

Bodis-Wollner I, Onofrj M (1987) The visual system in Parkinson’s disease. Adv Neurol 45:323–327PubMed

Bodis-Wollner I, Yahr MD (1978) Measurements of visual evoked potentials in Parkinson’s disease. Brain 101:661–671PubMedCrossRef

Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M (1987) Visual dysfunction in Parkinson’s disease. Loss in spatiotemporal contrast sensitivity. Brain 110(Pt 6):1675–1698PubMedCrossRef

Boudrault C, Bazinet RP, Kang JX, Ma DW (2010) Cyclooxygenase-2 and n-6 PUFA are lower and DHA is higher in the cortex of fat-1 mice. Neurochem Int 56:585–589PubMedCrossRef

Bourre JM, Bonneil M, Clement M, Dumont O, Durand G, Lafont H, Nalbone G, Piciotti M (1993) Function of dietary polyunsaturated fatty acids in the nervous system. Prostaglandins Leukot Essent Fatty Acids 48:5–15PubMedCrossRef

Bousquet M, Saint-Pierre M, Julien C, Salem N Jr, Cicchetti F, Calon F (2008) Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson’s disease. Faseb J 22:1213–1225PubMedCrossRef

Boyd JD, Jang H, Shepherd KR, Faherty C, Slack S, Jiao Y, Smeyne RJ (2007) Response to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res 1175:107–116PubMedCrossRef

Bulens C, Meerwaldt JD, Van der Wildt GJ, Van Deursen JB (1987) Effect of levodopa treatment on contrast sensitivity in Parkinson’s disease. Ann Neurol 22:365–369PubMedCrossRef

Buttner T, Kuhn W, Muller T, Heinze T, Puhl C, Przuntek H (1996) Chromatic and achromatic visual evoked potentials in Parkinson’s disease. Electroencephalogr Clin Neurophysiol 100:443–447PubMed

Buttner T, Muller T, Kuhn W (2000) Effects of apomorphine on visual functions in Parkinson’s disease. J Neural Transm 107:87–94PubMedCrossRef

Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ (2008) Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson’s disease. Neurosci Res 62:206–209PubMedCrossRef

Carlton PS, Gopalakrishnan R, Gupta A, Liston BW, Habib S, Morse MA, Stoner GD (2002) Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus. Cancer Res 62:4376–4382PubMed

Catalan J, Moriguchi T, Slotnick B, Murthy M, Greiner RS, Salem N Jr (2002) Cognitive deficits in docosahexaenoic acid-deficient rats. Behav Neurosci 116:1022–1031PubMedCrossRef

Chipuk JE, Bouchier-Hayes L, Green DR (2006) Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ 13:1396–1402PubMedCrossRef

Cudeiro J, Rivadulla C (1999) Sight and insight—on the physiological role of nitric oxide in the visual system. Trends Neurosci 22:109–116PubMedCrossRef

de Meira Santos Lima M, Braga Reksidler A, Marques Zanata S, Bueno Machado H, Tufik S, Vital MA (2006) Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 1101:117–125PubMedCrossRef

Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389PubMedCrossRef

Disshon KA, Dluzen DE (1997) Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release. Brain Res 764:9–16PubMedCrossRef

Dyer RS, Howell WE, MacPhail RC (1981) Dopamine depletion slows retinal transmission. Exp Neurol 71:326–340PubMedCrossRef

Feng Z, Li D, Fung PC, Pei Z, Ramsden DB, Ho SL (2003) COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 14:1927–1929PubMedCrossRef

Galli C, White HB Jr, Paoletti R (1971) Lipid alterations and their reversion in the central nervous system of growing rats deficient in essential fatty acids. Lipids 6:378–387PubMedCrossRef

Gasser T (2001) Molecular genetics of Parkinson’s disease. Adv Neurol 86:23–32PubMed

Gawel MJ, Das P, Vincent S, Rose FC (1981) Visual and auditory evoked responses in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 44:227–232PubMedCrossRef

Gemici B, Tan R, Ongut G, Izgut-Uysal VN (2010) Expressions of inducible nitric oxide synthase and cyclooxygenase-2 in gastric ischemia-reperfusion: role of angiotensin II. J Surg Res 161:126–133PubMedCrossRef

Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987–1041PubMedCrossRef

German OL, Insua MF, Gentili C, Rotstein NP, Politi LE (2006) Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway. J Neurochem 98:1507–1520PubMedCrossRef

Ghilardi MF, Bodis-Wollner I, Onofrj MC, Marx MS, Glover AA (1988a) Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain 111(Pt 1):131–149PubMedCrossRef

Ghilardi MF, Chung E, Bodis-Wollner I, Dvorzniak M, Glover A, Onofrj M (1988b) Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci 43:255–262PubMedCrossRef

Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson’s disease. Proc Natl Acad Sci USA 104:18754–18759PubMedCrossRef

Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson’s disease. J Neurosci 29:13543–13556PubMedCrossRef

Green P, Glozman S, Yavin E (2001) Ethyl docosahexaenoate-associated decrease in fetal brain lipid peroxide production is mediated by activation of prostanoid and nitric oxide pathways. Biochim Biophys Acta 1531:156–164PubMed

Hacioglu G, Agar A, Yargicoglu P (2006) The role of docosahexaenoic acid on visual evoked potentials in one kidney-one clip hypertension. Acta Ophthalmol Scand 84:488–494PubMedCrossRef

Hacioglu G, Kose O, Aslan M, Agar A (2007) Beneficial effects of docosahexaenoic acid on active avoidance performance in 1K-1C hypertensive rats. Neurobiol Learn Mem 87:159–165PubMedCrossRef

Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59:1609–1623PubMedCrossRef

Haobam R, Sindhu KM, Chandra G, Mohanakumar KP (2005) Swim-test as a function of motor impairment in MPTP model of Parkinson’s disease: a comparative study in two mouse strains. Behav Brain Res 163:159–167PubMedCrossRef

Harnois C, Di Paolo T (1990) Decreased dopamine in the retinas of patients with Parkinson’s disease. Invest Ophthalmol Vis Sci 31:2473–2475PubMed

Hetzler BE, Boyes WK, Creason JP, Dyer RS (1988) Temperature-dependent changes in visual evoked potentials of rats. Electroencephalogr Clin Neurophysiol 70:137–154PubMedCrossRef

Hoang T, Choi DK, Nagai M, Wu DC, Nagata T, Prou D, Wilson GL, Vila M, Jackson-Lewis V, Dawson VL, Dawson TM, Chesselet MF, Przedborski S (2009) Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radic Biol Med 47:1049–1056PubMedCrossRef

Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, Rakic P, Flavell RA (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson’s disease. Proc Natl Acad Sci USA 101:665–670PubMedCrossRef

Kabuto H, Amakawa M, Mankura M, Yamanushi TT, Mori A (2009) Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Neurochem Res 34:1299–1303PubMedCrossRef

Kang JM, Park HJ, Choi YG, Choe IH, Park JH, Kim YS, Lim S (2007) Acupuncture inhibits microglial activation and inflammatory events in the MPTP-induced mouse model. Brain Res 1131:211–219PubMedCrossRef

Kato H, Kurosaki R, Oki C, Araki T (2004) Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res 1030:66–73PubMedCrossRef

Kidd PM (2000) Parkinson’s disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern Med Rev 5:502–529PubMed

Kobayashi T, Araki T, Itoyama Y, Takeshita M, Ohta T, Oshima Y (1997) Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice. Life Sci 61:2529–2538PubMedCrossRef

Kremer JM, Lawrence DA, Jubiz W, DiGiacomo R, Rynes R, Bartholomew LE, Sherman M (1990) Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 33:810–820PubMedCrossRef

Langheinrich T, Tebartz van Elst L, Lagreze WA, Bach M, Lucking CH, Greenlee MW (2000) Visual contrast response functions in Parkinson’s disease: evidence from electroretinograms, visually evoked potentials and psychophysics. Clin Neurophysiol 111:66–74PubMedCrossRef

Lee JA, Song HY, Ju SM, Lee SJ, Kwon HJ, Eum WS, Jang SH, Choi SY, Park JS (2009a) Differential regulation of inducible nitric oxide synthase and cyclooxygenase-2 expression by superoxide dismutase in lipopolysaccharide stimulated RAW 264.7 cells. Exp Mol Med 41:629–637PubMedCrossRef

Lee SA, Kim HJ, Chang KC, Baek JC, Park JK, Shin JK, Choi WJ, Lee JH, Paik WY (2009b) DHA and EPA down-regulate COX-2 expression through suppression of NF-kappaB activity in LPS-treated human umbilical vein endothelial cells. Korean J Physiol Pharmacol 13:301–307PubMedCrossRef

Levant B, Ozias MK, Carlson SE (2007) Specific brain regions of female rats are differentially depleted of docosahexaenoic acid by reproductive activity and an (n-3) fatty acid-deficient diet. J Nutr 137:130–134PubMed

Lockwood AH (2000) Pesticides and parkinsonism: is there an etiological link? Curr Opin Neurol 13:687–690PubMedCrossRef

Matsui H, Udaka F, Tamura A, Oda M, Kubori T, Nishinaka K, Kameyama M (2005) The relation between visual hallucinations and visual evoked potential in Parkinson disease. Clin Neuropharmacol 28:79–82PubMedCrossRef

Mattammal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH (1995) Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson’s disease. J Neurochem 64:1645–1654PubMedCrossRef

McLaughlin P, Zhou Y, Ma T, Liu J, Zhang W, Hong JS, Kovacs M, Zhang J (2006) Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia 53:567–582PubMedCrossRef

Meissner W, Hill MP, Tison F, Gross CE, Bezard E (2004) Neuroprotective strategies for Parkinson’s disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 25:249–253PubMedCrossRef

Michael-Titus AT (2007) Omega-3 fatty acids and neurological injury. Prostaglandins Leukot Essent Fatty Acids 77:295–300PubMedCrossRef

Mills RD, Sim CH, Mok SS, Mulhern TD, Culvenor JG, Cheng HC (2008) Biochemical aspects of the neuroprotective mechanism of PTEN-induced kinase-1 (PINK1). J Neurochem 105:18–33PubMedCrossRef

Mitra N, Mohanakumar KP, Ganguly DK (1992) Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res Bull 28:355–364PubMedCrossRef

Murthy M, Hamilton J, Greiner RS, Moriguchi T, Salem N Jr, Kim HY (2002) Differential effects of n-3 fatty acid deficiency on phospholipid molecular species composition in the rat hippocampus. J Lipid Res 43:611–617PubMedCrossRef

Nicklas WJ, Vyas I, Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36:2503–2508PubMedCrossRef

Ogawa N, Mizukawa K, Hirose Y, Kajita S, Ohara S, Watanabe Y (1987) MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior. Eur Neurol 26(Suppl 1):16–23PubMedCrossRef

Onofrj M, Bodis-Wollner I (1982) Dopaminergic deficiency causes delayed visual evoked potentials in rats. Ann Neurol 11:484–490PubMedCrossRef

Onofrj M, Ghilardi MF, Basciani M, Gambi D (1986) Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J Neurol Neurosurg Psychiatry 49:1150–1159PubMedCrossRef

Pawlosky RJ, Bacher J, Salem N Jr (2001) Ethanol consumption alters electroretinograms and depletes neural tissues of docosahexaenoic acid in rhesus monkeys: nutritional consequences of a low n-3 fatty acid diet. Alcohol Clin Exp Res 25:1758–1765PubMedCrossRef

Peachey NS, Ball SL (2003) Electrophysiological analysis of visual function in mutant mice. Doc Ophthalmol 107:13–36PubMedCrossRef

Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 76:1265–1274PubMedCrossRef

Przybylkowski A, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A, Czlonkowska A, Czlonkowski A (2004) Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Res 1019:144–151PubMedCrossRef

Puskas LG, Bereczki E, Santha M, Vigh L, Csanadi G, Spener F, Ferdinandy P, Onochy A, Kitajka K (2004) Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain. Biochimie 86:817–824PubMedCrossRef

Reksidler AB, Lima MM, Zanata SM, Machado HB, da Cunha C, Andreatini R, Tufik S, Vital MA (2007) The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 560:163–175PubMedCrossRef

Sakamoto T, Cansev M, Wurtman RJ (2007) Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 1182:50–59PubMedCrossRef

Samadi P, Gregoire L, Rouillard C, Bedard PJ, Di Paolo T, Levesque D (2006) Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann Neurol 59:282–288PubMedCrossRef

Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54:823–827PubMedCrossRef

Schmidt N, Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson’s disease. J Neural Transm 108:1263–1282PubMedCrossRef

Schober A (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res 318:215–224PubMedCrossRef

Sedelis M, Schwarting RK, Huston JP (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson’s disease. Behav Brain Res 125:109–125PubMedCrossRef

Simopoulos AP (1989) Summary of the NATO advanced research workshop on dietary omega 3 and omega 6 fatty acids: biological effects and nutritional essentiality. J Nutr 119:521–528PubMed

Singh J, Hamid R, Reddy BS (1997) Dietary fat and colon cancer: modulation of cyclooxygenase-2 by types and amount of dietary fat during the postinitiation stage of colon carcinogenesis. Cancer Res 57:3465–3470PubMed

Strain GM, Tedford BL (1993) Flash and pattern reversal visual evoked potentials in C57BL/6J and B6CBAF1/J mice. Brain Res Bull 32:57–63PubMedCrossRef

Tanriover G, Seval-Celik Y, Ozsoy O, Akkoyunlu G, Savcioglu F, Hacioglu G, Demir N, Agar A (2010) The effects of docosahexaenoic acid on GDNF and NTN in bilateral rat model of Parkinson`s disease. Folia Histochem Cytobiol 48:434–441

Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S (2003) COX-2 and neurodegeneration in Parkinson’s disease. Ann N Y Acad Sci 991:272–277PubMedCrossRef

Temma K, Shimoya K, Zhang Q, Kimura T, Wasada K, Kanzaki T, Azuma C, Koyama M, Murata Y (2004) Effects of 4-hydroxy-2-nonenal, a marker of oxidative stress, on the cyclooxygenase-2 of human placenta in chorioamnionitis. Mol Hum Reprod 10:167–171PubMedCrossRef

Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE (2001) Essential fatty acids in visual and brain development. Lipids 36:885–895PubMedCrossRef

Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson’s disease. J Neuroinflamm 3:6CrossRef

Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39:359–407PubMedCrossRef

Wang T, Pei Z, Zhang W, Liu B, Langenbach R, Lee C, Wilson B, Reece JM, Miller DS, Hong JS (2005) MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. Faseb J 19:1134–1136PubMedCrossRef

Weisinger HS, Vingrys AJ, Bui BV, Sinclair AJ (1999) Effects of dietary n-3 fatty acid deficiency and repletion in the guinea pig retina. Invest Ophthalmol Vis Sci 40:327–338PubMed

Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G (2006) Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 1088:83–92PubMedCrossRef

Yao H, Tang X, Shao X, Feng L, Wu N, Yao K (2007) Parthenolide protects human lens epithelial cells from oxidative stress-induced apoptosis via inhibition of activation of caspase-3 and caspase-9. Cell Res 17:565–571PubMedCrossRef

Titel: The Effect of Docosahexaenoic Acid on Visual Evoked Potentials in a Mouse Model of Parkinson’s Disease: The Role of Cyclooxygenase-2 and Nuclear Factor Kappa-B
verfasst von: Ozlem Ozsoy
Gamze Tanriover
Narin Derin
Nimet Uysal
Necdet Demir
Burcu Gemici
Ceren Kencebay
Piraye Yargicoglu
Aysel Agar
Mutay Aslan
Publikationsdatum: 01.10.2011
Verlag: Springer-Verlag
Erschienen in: Neurotoxicity Research / Ausgabe 3/2011
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-011-9238-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Protective Effect of Curcumin and its Combination with Piperine (Bioavailability Enhancer) Against Haloperidol-Associated Neurotoxicity: Cellular and Neurochemical Evidence

Regulation of Neuronal Activation by Alpha2A Adrenergic Receptor Agonist

Repeated Immobilization Stress Increases Nur77 Expression in the Bed Nucleus of the Stria Terminalis

The Neural Circuitry of Autism

Toxic Effects of Low Alcohol and Nicotine Combinations in SH-SY5Y Cells are Apoptotically Mediated